-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23, 2021, Bristol-Myers Squibb (BMS) announced that the U.
Hematopoietic stem cell transplantation is an effective method for the treatment of aggressive leukemia and other hematological malignancies, and is usually the only option for cure
GvHD occurs when donor T cells recognize the patient's healthy cells as foreign objects and start to attack
This sBLA application is based on the results of a phase 2 clinical trial of ABA2 and a trial based on real-world data
Reference materials:
[1] US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD).
(The original text has been deleted)